SCHEMBL23213595

SCHEMBL23213595

Cc1c(Cl)cc([N+](=O)[O-])cc1CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 3/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 1/20 0.34
GPR35 Q9HC97 1/20 0.34
NR1H4 Q96RI1 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
MAPT P10636 1/20 0.33
GPR55 Q9Y2T6 1/20 0.32
RAB9A P51151 3/20 0.32
GALR3 O60755 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21979436 0.83 HSD17B10 (0.45) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL21979360 0.78 ALDH1A1 (0.38) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL29796100 0.76 BACE1 (0.33) ALDH1A1
SCHEMBL23213299 0.76 BACE1 (0.33) ALDH1A1
SCHEMBL22498332 0.76 HTT (0.38) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL2103775 0.76 HTT (0.44) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL31474167 0.75 KMT2A (0.37) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL17494979 0.75 ALDH1A1 (0.36) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL21979353 0.75 IDO1 (0.36) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL21979443 0.74 TXNRD1 (0.38) ALDH1A1KMT2AMEN1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2022200857-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2022-09-29 WO disclosed
EP-4041231-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2022-08-17 EP disclosed
US-20220242846-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-08-04 US disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 ALDH1A1 4150/4885KMT2A 3292/4885MEN1 1094/4885
US-20220242846-A1 ISOINDOLINONE COMPOUNDS AOC2, AOC3, INF2 ALDH1A1 1331/4885KMT2A 2523/4885MEN1 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.